Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.72 |
| ▸ | KIT | P10721 | 9/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | CLK2 | P49760 | 1/20 | 0.61 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.61 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211639 | 0.91 | KIT (0.64) | MAP3K11KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL17200869 | 0.88 | KIT (0.91) | MAP3K11KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL721017 | 0.84 | MAP3K11 (1.00) | MAP3K11KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL8941707 | 0.83 | KIT (1.00) | MAP3K11KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL8941722 | 0.80 | KIT (0.74) | MAP3K11KITDYRK1ACLK1CLK2 | |
| SCHEMBL8941778 | 0.79 | DYRK1A (0.77) | MAP3K11KITDYRK1ACLK1CLK2 | |
| SCHEMBL15833894 | 0.79 | KIT (1.00) | KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL15555716 | 0.77 | KIT (0.86) | KITDYRK1AAAK1SLC2A1 | |
| SCHEMBL12763532 | 0.77 | DYRK1A (0.73) | MAP3K11KITDYRK1AAAK1CLK1 | |
| SCHEMBL12763536 | 0.77 | DYRK1A (1.00) | KITDYRK1AAAK1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | DYRK1A, DYRK3, DYRK2 | MAP3K11 309/4885KIT 4658/4885DYRK1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.